Nerve block may halt prostate cancer progression

NCT ID NCT06703437

Ongoing Disease control Sponsor: Icahn School of Medicine at Mount Sinai Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase trial tests whether a long-acting nerve block, given during a standard prostate biopsy, can slow the growth of high-risk prostate cancer. The block uses lidocaine and dehydrated alcohol to temporarily stop signals from nerves that may help cancer spread. Only 12 men with high-risk features will take part, and the main goal is to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dehydrated alcohol (ethanol) and lidocaine
What this could lead to: If it works, this could point toward a way to slow prostate cancer growth by blocking nerve signals.
What could go wrong: This is a very early phase 1 safety trial with only 12 people. It is designed to find a safe dose, not to prove the treatment works. Side effects from the nerve block are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.